• Gastrin I: Interpreting GI Organoid Evidence

  2026-10-05

  Gastrin I can clarify CCK2 receptor biology, but its interpretation in intestinal organoids requires careful separation of gastric acid secretion from intestinal pharmacokinetics. This evidence-focused guide connects human Gastrin I peptide research with the findings and limitations of hiPSC-derived intestinal organoid models.

• Triiodothyronine (T3): Research Context and Evidence

  2026-10-05

  Triiodothyronine is a biologically active thyroid hormone used as a research perturbation for studying receptor-mediated gene regulation, metabolism, growth, and development. This overview separates vendor-described product attributes from peer-reviewed evidence, explains conceptual applications in cellular metabolism assays and metabolic disorder research, and clarifies why findings from a recent oligodendrocyte gene-editing study should not be extrapolated to T3 biology.

• ATRX-Deficient Glioma Sensitivity to PDGFR Inhibitors

  2026-10-04

  The 2022 Cancers study by Pladevall-Morera and colleagues identifies ATRX deficiency as a context associated with greater sensitivity to selected receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination findings with temozolomide support ATRX-aware interpretation of targeted-therapy studies, while remaining primarily preclinical and cellular evidence.

• SEMA3E, Beige Fat, and β-Catenin Signaling

  2026-10-03

  A 2026 mouse study identifies SEMA3E as a regulator of beige adipocyte differentiation and non-shivering thermogenesis, linking its activity to mitochondrial respiration and Wnt/β-catenin signaling. The findings strengthen a mechanistic model of adipose tissue remodeling, while remaining primarily preclinical and requiring validation across species and disease contexts.

• Cediranib (AZD2171): Measure the Mechanism

  2026-10-02

  Cediranib (AZD2171) is more than an angiogenesis inhibitor: it is a practical probe for separating VEGFR signaling pathway suppression, growth inhibition, and cell death. This thought-leadership guide connects mechanism, assay design, and translational decision-making for cancer research.

• CAF Lactate, ANTXR1 Lactylation, and Oxaliplatin Resistance

  2026-10-01

  A 2025 Cancer Letters study identifies a CAF-to-colorectal cancer lactate circuit that links stromal glycolysis to ANTXR1 lactylation, cancer stemness, and oxaliplatin resistance. Its cell and xenograft evidence supports targeting the lactate shuttle as a strategy to improve chemotherapy response, while also highlighting the need for clinical validation of ANTXR1-related biomarkers.

• PFHxS Hepatotoxicity and PPARα Signaling in Zebrafish

  2026-10-01

  A 2024 Environmental Science & Technology study integrates transcriptomics, liver pathology, biochemical measurements, and targeted causal interventions to show that environmentally relevant PFHxS exposure can disrupt liver development and function in larval zebrafish. Its combination of pharmacological antagonism and PPAR morpholino knockdown provides a stronger mechanistic framework than pathway enrichment alone, while also defining important limits for translation to mammalian metabolic disease research.

• Epinephrine in Local Anesthesia: Dose and Systemic Effects

  2026-09-30

  This narrative review explains how epinephrine improves dental local anesthesia through vasoconstriction, prolonged neural blockade, reduced anesthetic absorption, and surgical hemostasis while also producing dose-dependent systemic effects. Its central practical conclusion is that 1:200,000 epinephrine is generally sufficient for effective anesthesia in many dental settings, limiting unnecessary cardiovascular exposure.

• Standardized Whole-Blood Immune Metabolism

  2026-09-30

  Zhao and colleagues introduce a standardized whole-blood stimulation protocol for examining how metabolic interventions reshape human immune responses. By combining defined immune stimuli, pathway-directed modulation, and cytokine measurements, the workflow offers a practical framework for reproducible cohort studies and translational immunometabolism research.

• 4-Hydroxytamoxifen Protocol and QC Guide

  2026-09-29

  4-Hydroxytamoxifen (SKU B6167) provides a DMSO-compatible estrogen receptor modulator for controlled cell, cancer, apoptosis, and cardiac myocyte workflows. It is appropriate for studies that can accommodate DMSO, but should not be selected when water or ethanol dissolution, long-term solution storage, or an already validated compound-specific dosing protocol is required.

• Linarin, Cyclin A2, and NSCLC Cell-Cycle Arrest

  2026-09-29

  A 2026 study identifies the Herba Patriniae flavonoid linarin as an inhibitor of non-small-cell lung cancer cell growth, linking its activity to G0/G1 arrest, senescence, apoptosis, and reduced Cyclin A2, Cyclin B1, and CHEK1 signaling. The work combines network pharmacology with EdU-based proliferation analysis, cell-cycle profiling, senescence assays, molecular docking, and immunoblotting to connect a botanical component with a defined cell-cycle phenotype.

• hiPSC Intestinal Organoids for Pharmacokinetics

  2026-09-28

  Saito and colleagues developed a streamlined three-dimensional culture strategy for generating expandable, cryopreservable intestinal organoids from human induced pluripotent stem cells. The resulting organoid-derived epithelial cells contained differentiated intestinal cell types and displayed cytochrome P450 and transporter activities, supporting more human-relevant in vitro pharmacokinetic studies.

• Z-DEVD-FMK Workflows for Cell-Death Studies

  2026-09-28

  Z-DEVD-FMK is a cell-permeable, irreversible caspase-3 inhibitor for testing executioner-caspase involvement in apoptosis assays, with additional activity against other caspases and calpains. This guide covers practical dosing and solubility choices—and explains why it is a pathway-comparison tool, not a direct inhibitor for studying caspase-1-driven pyroptosis.

• SuperSignal ECL Kit Ultrasensitive for Western Blots

  2026-09-27

  The SuperSignal ECL Chemiluminescent Substrate Detection Kit supports HRP-based Western blot protein detection, including femtogram-level bands under optimized conditions. This article explains how the SuperSignal ECL Kit Ultrasensitive can fit a CRSwNP ALOX5 research workflow while distinguishing product specifications from findings reported in the disease study.

• Spatially Concentrated ABEs Correct PLP1 Mutations

  2026-09-26

  The study introduces spatially concentrated adenine base editors that improve editing in oligodendrocytes by recruiting the deaminase to target sites, rather than simply increasing its catalytic activity. The compact cABE-2.0 design corrected a disease-associated PLP1 mutation in oligodendrocytes and improved myelination-related outcomes in the reported experiments, while reducing transcriptome-wide RNA off-target effects.

8468 records 1/565 page Next 12345 下5页 Last page